drugset / Trial / NCT00277836

Study Evaluating MST-997 in Advanced Malignant Solid Tumors

NCT00277836 ↗

Phase 1 Terminated 60 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
Non-randomizedFactorialOpen-labelTreatment

Summary

MST-997 is a taxane analog with the potential to treat subjects with a variety of tumor types. Preclinical data demonstrated that MST-997 inhibited tumor growth when administered intravenously (IV). This phase 1 dose escalation study is designed to evaluate the safety and tolerability of if IV MST-997 formulated in Polysorbate 80 Diluent can be safely administered on a weekly basis.

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject SIMOTAXEL Small molecule — Intravenous

Indications